A fully bioabsorbable drug-eluting stent (DES) shows improvements over its predecessor and competitive levels of target lesion failure (TLF) at 1 year, according to results published in the March 9, ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — A second-generation drug-eluting bioresorbable scaffold made of magnesium alloy appears to be a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. WASHINGTON — Patients with de novo coronary artery ...

SAN FRANCISCO, CA — Drug-eluting stents (DES) made of bioresorbable polymers may be all the rage, but some investigators see advantages in such "disappearing" coronary stents made of metal. In a small ...

A drug-eluting absorbable metal scaffold offers favorable performance and safety at 6 months, according to results from the first-in-human BIOSOLVE-II trial reported at TCT 2015 and simultaneously ...

World-class bioprocess modelling software developer unveils new customisable features for users. LONDON, 11 December 2019 – Biopharm Services, the bioprocess analysis software developer, today ...

Biotronik announced that the second clinical trial of its Dreams drug-eluting bioresorbable stent met another milestone as it races to become the third player in the emerging space. The Biosolve-II ...

For over 30 years Greyhound Chromatography has been supplying high quality products to laboratories around the world and is delighted to add Biosolve’s range to their expanding product portfolio. The ...

Biotronik has received a CE mark for its bioresorbable scaffold. The device, intended for the treatment of coronary artery disease without using a permanent implant, is the first clinically proven ...